Pharmacology revision checklist for NEET PG, INI-CET & FMGE

Loading dose set by Vd and target level, not clearance

Steady-state level from infusion rate over clearance

Phase I first-in-human safety and dose finding

Phase III comparative efficacy and Phase IV surveillance

Multicentre RCT design and evidence hierarchy

Muscarinic actions and methacholine receptor target

Cholinomimetic uses and the COPD retention trap

Irreversible acetylcholinesterase phosphorylation mechanism

Atropine plus pralidoxime and the atropine-toxicity clue

Pinpoint-pupil causes and the belladonna exception

Mirabegron beta-3, dopamine dose windows, alpha-2 actions

Adrenaline dual action and lid-retraction sympathomimetics

Fenoldopam D1 agonism and noradrenaline shock response

Three-drug blood-pressure and heart-rate tracing analysis

Low-dose aspirin COX-1 antiplatelet action and NSAID myths

Aspirin overdose mixed acid-base and urinary alkalinisation

Xanthine oxidase inhibitors and pegloticase uricase

Colchicine microtubule inhibition in acute gout

Aspirin bidirectional effect on urate excretion

PCSK9 inhibitors, bempedoic acid and CETP inhibitors

Statin drug interaction and post-MI high-intensity target

Niacin flushing, hyperglycaemia and hepatotoxicity

Amiodarone thyroid, pulmonary and skin toxicity

Antiarrhythmic class use and AF drug exclusion

Ranolazine late inward sodium-current block

First-line exceptions and thiazide combination efficacy

ACE inhibitor, ARB and aliskiren renin-axis actions

Pulmonary hypertension, mild HTN and edema-sparing choice

Thiazide DCT and furosemide thick-ascending-limb sites

Vasopressin antagonist collecting-duct action

Mannitol for raised ICP, aldosterone antagonist for ascites, metolazone in renal failure

Acetazolamide for mountain sickness and CKD-safe agents

SGLT2 inhibitor cardiorenal benefit and genital infection risk

Linagliptin and DPP4 choice in advanced CKD

GIP/GLP-1 enhancement lowering glucagon

Teriparatide bone formation and its complications

Bisphosphonate first-line use, non-agents and dosing

Hypercalcaemia first step and PTH-lowering agents

Absence, focal and juvenile-myoclonic first-line matching

Stopping antiepileptics after a seizure-free interval

Gabapentinoids for neuropathic pain and topiramate uses

Antiemetic extrapyramidal reaction and migraine prophylaxis

Drugs worsening myasthenia and succinylcholine block features

Lithium Ebstein anomaly and toxic serum levels

Paraldehyde odour clue and narcoanalysis drug

Distinguishing prodrugs from active agents

Clozapine agranulocytosis monitoring

Twelve-hour trough timing for lithium level monitoring

Lithium anti-suicidal role and toxicity warning signs

Valproate hyperammonaemia and pregnancy avoidance

Tiagabine GAT-1 block and aprepitant NK1 antagonism

Rivastigmine patch for non-adherent dementia

Retigabine Kv7 opener as add-on for focal seizures

Propofol infusion syndrome, injection pain and etomidate adrenal suppression

Thiopentone cerebroprotection and redistribution kinetics

Ketamine NMDA action and induction-agent selection

Blood-gas solubility, onset speed and diffusion hypoxia

Potency sequence and inhalational cardiac depression

Dalton partial-pressure law and trilene soda-lime reaction

Glycopyrrolate and scopolamine premedication effects

Dexmedetomidine natural-sleep sedation

Most potent analgesic gas and reflex least affected

Effects not caused by midazolam

Vitamin-K factor carboxylation, PT monitoring and bleeding interactions

Protein-C mediated warfarin skin necrosis

Antithrombin adjuvant action and LMWH advantages

Hydroxyurea reducing pain crises and non-useful agents

GM-CSF and thrombopoietic agents for chemo cytopenia

Tyrosine kinase inhibitor approved in ITP

Aminophylline PDE inhibition and adenosine antagonism

Theophylline diuresis and fluoroquinolone interaction

Effects wrongly attributed to salbutamol

Epinephrine beta-2 bronchodilation and refractory response

PPI identification, long-term effects, half-life and CYP inhibition

Sucralfate chelation timing with phenytoin and ranitidine

Pirenzepine M1 antagonism for peptic ulcer

Metoclopramide receptor action and extrapyramidal reaction

Aprepitant/ondansetron for cisplatin-induced vomiting

Isoniazid mycolic-acid/catalase action and pyridoxine-responsive neuropathy

Ethambutol ocular toxicity and sterilising/resistance-preventing agents

Rifampicin RNA-polymerase block, OCP interaction and rifabutin

Emtricitabine pigmentation, indinavir stones and didanosine pancreatitis

Tesamorelin lipodystrophy and ART-related bleeding risk

Post-exposure prophylaxis and prevention of mother-to-child transmission

Rifampicin-ART interaction and NACO second-line regimens

Amphotericin ergosterol binding, liposomal form and potassium loss

Voriconazole for aspergillosis, oral thrush and cutaneous lesion therapy

Nail lacquers, griseofulvin resistance and antifungal mechanisms

Cyclophosphamide active metabolite and temozolomide class

Methotrexate DHFR block, pemetrexed rescue and urine alkalinisation

Cladribine for hairy-cell leukaemia and L-asparaginase in ALL

Anticancer drug identification from clinical images

Chemotherapy and toxin drug-antidote matching